Should I Buy ANNX? ANNX 2026 Analysis

Should You Buy Annexon Inc (ANNX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

5.730

1 Day change

1.78%

52 Week Range

7.180

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: no proprietary buy signals today and near-term momentum is weakening.
Price is sitting right on key support (~6.03–6.04). That can produce a bounce, but the MACD is still deteriorating and the pattern stats show slightly negative 1-month edge.
Options positioning is structurally bullish (very low OI put/call), but today’s flow is closer to neutral and overall volume is light, so there’s no strong “risk-on” confirmation.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Pre-market price ~6.02–6.04 (-0.33%) is essentially on S1 support at 6.035; a clean break below increases downside risk toward S2 ~5.733.
Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting the broader trend structure is still constructive.
MACD histogram -0.0907 and negatively expanding = bearish momentum building despite bullish MA stack (often seen during pullbacks inside an uptrend).
RSI_6 38.34: weak/near-oversold but not a confirmed reversal signal.
Upside levels to reclaim for a momentum turn: Pivot 6.524, then R1 7.013 (clear breakout zone).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Open interest put/call 0.14: positioning/skew is strongly call-heavy (bullish longer-horizon sentiment).
Volume put/call 0.94: today’s trading flow is near neutral (puts ~133 vs calls ~142).
Options activity is light vs normal: today volume is ~33% of 30-day average (275 contracts), so sentiment read is lower confidence.
Implied vol 30D ~102.9% vs historical vol ~81.6% (options pricing in big moves); IV has been cooling vs 5D/10D IV averages (~126/124), implying reduced near-term event fear.

Technical Summary

Sell

Buy

Positive Catalysts

- Long-term thesis focus: complement C1q inhibitor programs (tanruprubart / vonaprument) with large-market indications referenced by analysts (e.g., GA, GBS).

Neutral/Negative Catalysts

- No fresh news catalysts in the last week; without a trigger, weak momentum can persist.
- Momentum signals are currently unfavorable (MACD worsening; RSI weak), increasing odds support breaks.
- Biotech profile with no revenue and high IV: price can drift or gap on trial/probability-of-success changes.
- 1-month pattern projection provided is slightly negative (approx -1.02%), suggesting limited near-term edge for buying immediately.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: 0 (pre-commercial stage).
Net loss improved YoY: Net Income -54.922M, +57.71% YoY (loss narrowing).
EPS improved YoY: -0.37, +48% YoY.
Overall: financials show better cost control, but the story remains primarily pipeline/timeline-driven rather than revenue-driven.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

2025-12-23 (Chardan): Initiated Buy, PT $16 (commercial potential + upside indications).
2025-11-19 (Wells Fargo): Overweight, PT raised $27 from $14 (higher probability-of-success assumption; “asymmetric” upside framing).
2025-11-16 (BofA): Buy, PT lowered $8 from $9 (model update post-Q3).
Wall St pros: strong upside optionality if Phase 3/clinical probabilities improve; multiple bullish ratings.
Wall St cons: wide dispersion of targets ($8 to $27) signals high uncertainty; near-term price action can be dominated by sentiment/probability revisions rather than fundamentals.

8 Analyst Rating

Wall Street analysts forecast ANNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANNX is 14.71 USD with a low forecast of 8 USD and a high forecast of 27 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.630

Low

Averages

14.71

High

Current: 5.630

Low

Averages

14.71

High

Chardan

Daniil Gataulin

Buy

initiated

$16

AI Analysis

2025-12-23

Reason

Chardan

Daniil Gataulin

Price Target

$16

AI Analysis

2025-12-23

initiated

Buy

Reason

Chardan analyst Daniil Gataulin initiated coverage of Annexon with a Buy rating and $16 price target. The firm cites the commercial potential of the company's complement C1q inhibitors tanruprubart in Guillain-Barre syndrome and vonaprument in geographic atrophy for the Buy rating. It sees additional upside potential from tanruprubart in Huntington's disease.

Wells Fargo

NULL

Overweight

upgrade

$14 -> $27

2025-11-19

Reason

Wells Fargo

Price Target

$14 -> $27

2025-11-19

upgrade

NULL

Overweight

Reason

Wells Fargo raised the firm's price target on Annexon to $27 from $14 and keeps an Overweight rating on the shares. The firm is raising its probability of success to 55% from 10% that vonaprument's Phase 3 trial in GA will be positive in the second half of 2026. Wells believes the setup offers a significant, asymmetric risk/reward skew with the potential for VC-like upside in the next 12 months.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ANNX

Unlock Now

ANNX Should I Buy

ANNX Should I Buy

Should You Buy Annexon Inc (ANNX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch